Live Breaking News & Updates on University Of Rochester School Medicine

Stay updated with breaking news from University of rochester school medicine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Approves Expanded Age Indication for Arexvy RSV Vaccine

The expanded indication is for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in adults aged 50 through 59 years who are at an increased risk. ....

Tony Wood , Advisory Committee On Immunization Practices , University Of Rochester School Medicine , Immunization Practices , Immune Response , Vaccine Against Respiratory Syncytial Virus Given , Including Adults , Increased Risk , Older Adults , Rochester School ,

US FDA Approves Expanded Age Indication for GSK's AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk Seite 1

08.06.2024 - GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through . Seite 1 ....

Annr Falsey , Tony Wood , University Of Rochester School Medicine , Business Wire , Chief Scientific Officer , Rochester School ,